Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2012 / Cilt: 22 - Sayı: 2

Kemoterapiye bağlı kusmanın kontrolünde Hidroksizinin rolü: Randomize klinik çalışma

Effect of Hydroxyzine in controlling acute chemotherapy-induced vomiting in children: A randomised trial

Pages
99–106
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Hydroxyzine may enhance the activity of ondansetron in controlling acute chemotherapy-induced emesis and provided a better performance and lesser symptom distress.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Nausea and vomiting are one of the most important side effects of chemotherapy.
📊
Key Findings & Data:Psychological factors such as anxiety, fear and negative moods have significant role in the chemotherapy induced emesis.
💡
Conclusion & Impact:Hydroxyzine may enhance the activity of ondansetron in controlling acute chemotherapy-induced emesis and provided a better performance and lesser symptom distress.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Nausea and vomiting are one of the most important side effects of chemotherapy. Psychological factors such as anxiety, fear and negative moods have significant role in the chemotherapy induced emesis. Each chemotherapy course cause state anxiety like an invasive medical procedure. Therefore, we aimed to evaluate the effect of addition a sedative-anxiolytic agent to a 5-HT3 receptor antagonist in improving the control of chemotherapy induced emesis. Seventy chemotherapy courses in 18 children who received at least one highly emotogenic drugs were interpreted. Courses were randomly assigned to receive ondansetron (group I) or ondansetron plus hydroxyzine as a sedative agent (group II). Control of emesis was evaluated according to Soukop-Smith criteria. Performance of patients and degree of symptoms was assessed by using Lansky Play-Performance Scale and the Symptom Distress Scale, respectively. The complete and major control rate of acute emesis in group II (56%) was higher than group I (22%) (p= 0.006). The effect of combination antiemetic therapy was more obvious in female than male (p= 0.03), and in patients whose age greater than 10 years (p= 0.02). The mean play performance scale and symptom distress scale score were similar in two groups, before the chemotherapy course. After completion of course, play performance and symptom distress scale score were significantly better in group-II than that of group-I. Patients and parents in group-II declared significantly better sleeping quality, appetite, activity and mood than group-I. Hydroxyzine may enhance the activity of ondansetron in controlling acute chemotherapy-induced emesis and provided a better performance and lesser symptom distress.

Özet

Bulantı ve kusma kemoterapinin en önemli yan etkilerinden biridir. Anksiyete, korku, negatif ruh hali gibi psikolojik faktörler kemoterapiye bağlı kusmada önemlidir. Bu nedenle çalışmamızda, 5-HT3 reseptor antagonistlerine sedatif anksiyolotik ajan olarak hidroksizin eklenmesinin kemoterapiye bağlı emezisin kontrolündeki rolünün araştırılması amaçlanmıştır. Onsekiz hastaya uygulanan ve yüksek emotojen kemoterapötik ajan içeren 70 kür değerlendirildi. Kürler rastgele olarak ondansetron (grup I) veya ondansetron+ hidroksizin (grup II) grubuna dahil edildi. Emezisin kontrolü Soukop-Smith kriterlerine gore değerlendirildi. Hastaların performansı Lansky Oyun-Performans Skalası ile semptomların derecesi Semptom Distres Skalası ile değerlendirildi. Grup I’deki hastaların %22’de, grup- II’deki hastaların ise %56’sında emezisin tam veya major kontrolü sağlanmıştır (p= 0.006). Kombinasyon antiemetik tedavinin etkinli- ği kızlarda erkelerden daha aşikardı (p= 0.03). Ondansetron+Hidroksizin kombinasyonu 10 yaş üstünde daha küçük çocuklara göre daha etkin kontrol sağlamaktaydı (p= 0.02). Kemoterapi kürü öncesinde iki grubun oyun performans ve semptom distress skalaları ortalama değerleri arasında önemli bir farklılık yoktu. Ancak kemoterapi kürü sonrasında ise her iki skalanın ortalama değerleri grup- II’de grup I’den daha yüksekti. Hastalar ve aileleri tarafından bildirilen iştah, uyku kalitesi, aktivite ve ruh halinin grup-II’de grup-I’den daha iyi olduğu belirlendi. Antiemetik tedavide hydroksizinin ile ondansetronun birlikte uygulanmasının emezisin kontrolünü arttırdığı ve daha iyi bir performans ve daha az semptom distres sağladığı belirlendi.

🔖

Cite This Article

KURUCU, N., DURMAZ, M. (2012). Kemoterapiye bağlı kusmanın kontrolünde Hidroksizinin rolü: Randomize klinik çalışma. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 22 - Sayı: 2, 99–106. https://ajindex.com/articles/323317

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Bryant R. Managing side effects of childhood cancer treatment. J Pediatr Nurs 18:113-125; 2003
  2. Antonarakis ES, Hain RDW. Nausea and vomiting associated with cancer chemotherapy: drug management in theory and in practice. Arch Dis Child 89: 877- 880, 2004
  3. Oo TH, Hesketh PJ. Drug insight: new antiemetics in the management of chemotherapy induced nausea and vomiting. Nat Clin Pract Oncol 2: 196-201, 2005
  4. LeBaron S, Zelter LK, LeBaron C, et al. Chemotherapy side effects in pediatric oncology patients: drugs, age, and sex as risk factors. Med Pediatr Oncol 16: 263- 268, 1998
  5. Hesketh PJ. Defining emogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist 4: 191-196, 1999
  6. Skoup M. A comparison of two dose levels of granisetron in patients receiving high dose cisplatin. Eur J Cancer 26 (Suppl.1): 15-19, 1990
  7. Smith IE. A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. Eur J Cancer 26 (suppl 1): 19-23, 1990
  8. Lansky SB, List MA, Lansky LL, et al. The measurement of performance in childhood cancer patients. Cancer 60: 1651-56, 1987
  9. McCorcle R, Cooley M, Shea JA. A user’s manual for the Symptom Distress Scale. Philadelphia, University of Pennsylvania- National Institute of Nursing Research, 1998
  10. McCorcle R, Young K. Development of a symptom distress scale. Cancer Nurs 5: 373-378, 1978
  11. Sarna L. Correlates of symptom distress in women with lung cancer. Cancer Pract 1: 21-28, 1993
  12. Hinds PS, Quargnenti A, Bush AJ, et al. An evaluation of the impact of a self-care coping intervention on psychological and clinical outcomes in adolescents with newly diagnosed cancer. Eur J Oncol Nurs 4: 6- 17, 2000
  13. Ergun M. Bilimsel araflt›rmalarda bilgisayarla istatistik uygulamalar›. Ankara, Ocak yay›nlar›, 1995
  14. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 358: 2482-2494, 2008
  15. Burish TG, Carey MP, Kozely MG, Greco FA. Conditioned side effects induced by cancer chemotherapy: prevention through behavioral treatment. J Consult Clin Psychol 55: 42-48,1987
  16. Patenaude AF, Kupst MJ. Psychosocial functioning in pediatric cancer. J Pediatr Psychol 30: 9-27, 2005
  17. Tyc VL, Mulhern RK, Barclay DB, et al. Variables associated with anticipatory nausea and vomiting in pediatric cancer patients receiving ondansetron antiemetic. J Pediatr Psychol 22: 45-58,1997
  18. Redd WH, Jacobsen PB, Die-Trill M, et al. Cognitive/ Att